7 completed. 2 Not applicable, 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Centre for Probe Development and Commercialization: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy PET Scan, [18F]PSMA-1007 Injection, Sodium MRI - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Completed | Glenn Bauman | 16 | 2021-02-04 | 2026-09-18 |
| Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer. [18F] PSMA-1007 Injection - Prostate Cancer Recurrent, Recurrent Prostate Cancer | Phase 3 | Completed | Centre for Probe Development and Commercialization | 100 | 2020-12-21 | 2024-02-07 |
| PSMA-PET Registry for Recurrent Prostate Cancer [18F]-DCFPyL or [18F]PSMA-1007 PET/ CT scan (PSMA PET) - Recurrent Prostate Cancer | Not applicable | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 9684 | 2018-09-27 | 2026-07-17 |
| A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients Cyclotron-produced 99mTc, Generator-produced 99mTc - Hyperthyroidism | Not applicable | Completed | British Columbia Cancer Agency | 60 | 2015-10-01 | 2023-02-21 |
| A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours [I-124]-CPD-1028 Injection, CPD-1061 - Cancer | Phase 1 | Completed | Centre for Probe Development and Commercialization | 2 | 2014-06-01 | 2016-10-18 |
| Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). Arm 1 - GEH120714 (18F) Injection - Relapsing-remitting Multiple Sclerosis (rrMS) | Phase 1 | Completed | GE Healthcare | 30 | 2013-04-01 | 2017-02-24 |
| A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function Renal Function Impairment | Completed | Centre for Probe Development and Commercialization | 6 | 2012-09-01 | 2014-04-09 |
Prostatic Neoplasms (3) · Hyperthyroidism (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Neoplasms (1)
Injections (1) · Multiparametric Magnetic Resonance Imaging (1) · Positron-Emission Tomography (1) · Tomography, X-Ray Computed (1)
Canada (7)
Eric Burak, PhD (1) · Francois Benard, MD (1) · Glenn Bauman, MD, FRCPC (1) · Karen Gulenchyn, MD (1) · Paul Sherwin, M.D. (1) · Stephen Pautler, MD, FRCSC (1) · Ur Metser, MD, FRCPC (1)